Johnson & Johnson has submitted two additional Biologics License Applications to the FDA. These applications seek approval for the use of TREMFYA in treating children aged 6 and older with moderate-to-severe plaque psoriasis, as well as those aged 5 and older with active juvenile psoriatic arthritis.
According to Liza O'Dowd, Vice President and Leader of the Immunodermatology Disease Area at Johnson & Johnson Innovative Medicine, there remains a significant unmet need in treating children and adolescents with these dermatological and joint conditions. These conditions can severely affect both their appearance and physical functionality.
TREMFYA is notable for being the first monoclonal antibody approved that specifically targets the p19 subunit of IL-23, thereby blocking its interaction with the IL-23 receptor.
